Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial
The REACH Trial Investigators
Research output: Contribution to journal › Article › peer-review
759Scopus
citations
Fingerprint
Dive into the research topics of 'Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial'. Together they form a unique fingerprint.
Keyphrases
Medicine and Dentistry
Pharmacology, Toxicology and Pharmaceutical Science